Simulations to Assess Phase II Noninferiority Trials of Different Doses of Capecitabine in Combination With Docetaxel for Metastatic Breast Cancer

A phase II trial in metastatic breast cancer (MBC) (NO16853) failed to show noninferiority (progression-free survival, PFS) of capecitabine 825 mg/m(2) plus docetaxel 75 mg/m(2) to the registered capecitabine dose of 1,250 mg/m(2) plus docetaxel 75 mg/m(2). We developed a modeling framework based on...

Descripción completa

Detalles Bibliográficos
Autores principales: Bruno, R, Lindbom, L, Schaedeli Stark, F, Chanu, P, Gilberg, F, Frey, N, Claret, L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3600724/
https://www.ncbi.nlm.nih.gov/pubmed/23835839
http://dx.doi.org/10.1038/psp.2012.20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3600724/
https://www.ncbi.nlm.nih.gov/pubmed/23835839
http://dx.doi.org/10.1038/psp.2012.20

Ejemplares similares